When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Amicus Therapeutics (FOLD) missed Q1 2019 revenue estimates by $3.8 million, but the underlying growth trends for Galafold look very strong. The revenue miss was driven by currency headwinds and ordering patterns. A similar situation happened in Q3 2018 and management noted on the earnings call that Galafold revenues should be stronger in Q2 and Q4 and weaker in Q1 and Q3. Amicus is also actively working to get the phase 3 study of AT-GAA in Pompe disease fully enrolled before the end of 2019 and the gene therapy pipeline should start getting